secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenwich LifeSciences, Inc. (GLSI)
CIK:        0001799788
Form:       8-K
Filed at:   2022-07-12T23:59:59+00:00
Accession:  0001493152-22-019038
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA removes clinical hold on Greenwich LifeSciences' Flamingo-01 Phase III trial
--------------------------------------------------------------------------------

- FDA formally removed the clinical hold on July 11, 2022, allowing the Flamingo-01 Phase III trial to proceed.
- Clinical hold was related to manufacturing and pharmacy process issues; company has addressed them with additional testing commitments.
- Company has begun site initiation visits and will provide future updates on trial progress.
- GLSI-100 is the drug candidate under development for breast cancer immunotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799788/000149315222019038/0001493152-22-019038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799788/000149315222019038/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-019038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer